Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Eiger BioPharmaceuticals stock

EIGR
US28249U1051
A2AF9X

Price

8.50
Today +/-
+0
Today %
+0 %
P

Eiger BioPharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Eiger BioPharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Eiger BioPharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Eiger BioPharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Eiger BioPharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Eiger BioPharmaceuticals Stock Price History

DateEiger BioPharmaceuticals Price
9/30/20248.50 undefined
9/27/20248.50 undefined

Eiger BioPharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Eiger BioPharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Eiger BioPharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Eiger BioPharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Eiger BioPharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Eiger BioPharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Eiger BioPharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Eiger BioPharmaceuticals’s growth potential.

Eiger BioPharmaceuticals Revenue, EBIT and net profit per share

DateEiger BioPharmaceuticals RevenueEiger BioPharmaceuticals EBITEiger BioPharmaceuticals Net Income
2029e165.05 M undefined599.34 M undefined59.33 M undefined
2028e56.94 M undefined14.42 M undefined5.43 M undefined
2027e36.87 M undefined-4.21 M undefined-4.08 M undefined
2026e35.04 M undefined-5.14 M undefined-150,960 undefined
2025e33.31 M undefined-6.35 M undefined-5.43 M undefined
2024e25.72 M undefined-21.97 M undefined-23.55 M undefined
202315.77 M undefined-71.78 M undefined-74.96 M undefined
202213.48 M undefined-92.74 M undefined-96.78 M undefined
202112.14 M undefined-76.94 M undefined-33.92 M undefined
20200 undefined-62.15 M undefined-65.05 M undefined
20190 undefined-68.9 M undefined-70.25 M undefined
20180 undefined-51.05 M undefined-52.39 M undefined
20170 undefined-41.52 M undefined-42.45 M undefined
20160 undefined-46.12 M undefined-47.09 M undefined
20150 undefined-12.97 M undefined-13.32 M undefined
20140 undefined-1.52 M undefined-1.52 M undefined
20130 undefined-19.96 M undefined-23.96 M undefined
20120 undefined-15.95 M undefined-16.21 M undefined
20110 undefined-6.03 M undefined-6.99 M undefined
20100 undefined-6.03 M undefined-6.99 M undefined

Eiger BioPharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000000000001213152533353656165
------------8.3315.3866.6732.006.062.8655.56194.64
-----------91.6784.62100.00------
00000000000111115000000
-6-6-15-19-1-12-46-41-51-68-62-76-92-71-21-6-5-414599
------------633.33-707.69-473.33-84.00-18.18-14.29-11.1125.00363.03
-6-6-16-23-1-13-47-42-52-70-65-33-96-74-23-50-4559
--166.6743.75-95.651,200.00261.54-10.6423.8134.62-7.14-49.23190.91-22.92-68.92-78.26---225.001,080.00
1.141.141.141.180.190.216.018.7313.7122.7928.1433.9441.631.48000000
--------------------
Details

Keystats

ⓘ

Revenue and Growth

The Eiger BioPharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Eiger BioPharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
0.532.618.484.94.859.941.8100.495128.888.898.925.44
00000000002.61.71.68
0000000000000
00000000002.62.91.56
00.30.23.10.70.60.71.55.499.4149.16
0.532.918.6885.560.542.5101.9100.4137.8103.4117.537.84
0.10.10.30.800.10.10.22.21.91.31.30.63
02.90000000017.300
0000000000000
0000000000000
0000000000000
002.30.300.10.30.42.53.94.51.30.36
0.132.61.100.20.40.64.75.823.12.60.99
0.635.921.289.15.560.742.9102.5105.1143.6126.5120.138.83
                         
62.257.865.5022.600000000
064.261.6218.51.6117.1141.3237.8297.9401.5412.9492.8497.87
-76.9-92.6-112.6-146.4-29.3-76.4-118.8-171.2-241.4-306.5-340.4-437.2-512.16
0000000000-0.1-0.3-0.17
0000000000000
-14.729.414.572.1-5.140.722.566.656.59572.455.3-14.46
0.60.61.43.31.92.63.25.86.44.67.892.12
2.41.233.312.62.14.210.51214.316.110.05
001.10000000000
12.40105.400000000
00000020007.8041.12
15.41.86.56.68.35.27.31016.916.629.925.153.28
00010.1014.713.125.630.431.22439.60
0000000000000
0000.32.3000.21.30.70.10.10
00010.42.314.713.125.831.731.924.139.70
15.41.86.51710.619.920.435.848.648.55464.853.28
0.731.22189.15.560.642.9102.4105.1143.5126.4120.138.83
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Eiger BioPharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Eiger BioPharmaceuticals's financial health and stability.

Assets

Eiger BioPharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Eiger BioPharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Eiger BioPharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Eiger BioPharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20102011201120122013201420152016201720182019202020212022
-6-6-2-15-20-1-13-47-42-52-70-65-33-96
00000000000000
00000000000000
00001011040-5-10
110010274567-3612
00000000012222
00000000000000
-5-5-1-14-16-1-9-37-38-42-63-63-71-83
00000000000000
000-211000-422-29-16-44619
000-211000-422-28-16-44619
00000000000000
441010514094005
000450175019915497371
44149011365191005897376
0004-1000000000
00000000000000
-1-1013-50422429-21-10-63
-5.61-5.61-1.58-14.69-16.29-1.28-9.18-38.03-38.41-42.81-64.09-63.45-71.57-83.35
00000000000000

Eiger BioPharmaceuticals stock margins

The Eiger BioPharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Eiger BioPharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Eiger BioPharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Eiger BioPharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Eiger BioPharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Eiger BioPharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Eiger BioPharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Eiger BioPharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Eiger BioPharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Eiger BioPharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Eiger BioPharmaceuticals Margin History

Eiger BioPharmaceuticals Gross marginEiger BioPharmaceuticals Profit marginEiger BioPharmaceuticals EBIT marginEiger BioPharmaceuticals Profit margin
2029e99.9 %363.13 %35.95 %
2028e99.9 %25.32 %9.54 %
2027e99.9 %-11.4 %-11.05 %
2026e99.9 %-14.67 %-0.43 %
2025e99.9 %-19.05 %-16.32 %
2024e99.9 %-85.42 %-91.55 %
202399.9 %-455.07 %-475.26 %
202286.42 %-687.98 %-717.95 %
202193.9 %-633.77 %-279.41 %
202099.9 %0 %0 %
201999.9 %0 %0 %
201899.9 %0 %0 %
201799.9 %0 %0 %
201699.9 %0 %0 %
201599.9 %0 %0 %
201499.9 %0 %0 %
201399.9 %0 %0 %
201299.9 %0 %0 %
201199.9 %0 %0 %
201099.9 %0 %0 %

Eiger BioPharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Eiger BioPharmaceuticals earnings per share therefore indicates how much revenue Eiger BioPharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Eiger BioPharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Eiger BioPharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Eiger BioPharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Eiger BioPharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eiger BioPharmaceuticals Revenue, EBIT and net profit per share

DateEiger BioPharmaceuticals Sales per ShareEiger BioPharmaceuticals EBIT per shareEiger BioPharmaceuticals Earnings per Share
2029e111.52 undefined0 undefined40.09 undefined
2028e38.47 undefined0 undefined3.67 undefined
2027e24.91 undefined0 undefined-2.75 undefined
2026e23.68 undefined0 undefined-0.1 undefined
2025e22.5 undefined0 undefined-3.67 undefined
2024e17.38 undefined0 undefined-15.91 undefined
202310.68 undefined-48.62 undefined-50.78 undefined
20220.32 undefined-2.23 undefined-2.32 undefined
20210.36 undefined-2.27 undefined-1 undefined
20200 undefined-2.21 undefined-2.31 undefined
20190 undefined-3.02 undefined-3.08 undefined
20180 undefined-3.72 undefined-3.82 undefined
20170 undefined-4.76 undefined-4.86 undefined
20160 undefined-7.67 undefined-7.84 undefined
20150 undefined-61.76 undefined-63.43 undefined
20140 undefined-8 undefined-8 undefined
20130 undefined-16.92 undefined-20.31 undefined
20120 undefined-13.99 undefined-14.22 undefined
20110 undefined-5.29 undefined-6.13 undefined
20100 undefined-5.29 undefined-6.13 undefined

Eiger BioPharmaceuticals business model

Eiger BioPharmaceuticals Inc is a US biopharmaceutical company that specializes in developing therapeutics for rare and serious diseases. It was founded in 2008 and is headquartered in Palo Alto, California. The company's history is closely tied to the discovery of hepatitis C medications, and their business model focuses on developing antiviral therapies for rare and severe diseases. They have multiple divisions dedicated to different therapeutic areas, including hepatitis C, hepatitis D, fibrosis, and lysosomal storage disorders. They currently offer several products, including Zokinvy for chronic hepatitis C infection and Lambda for hepatitis D. They have also formed strategic partnerships with other pharmaceutical companies to support the development and commercialization of their products. Overall, Eiger BioPharmaceuticals Inc is known for its innovative approach and commitment to improving treatment options for patients with serious medical needs. Eiger BioPharmaceuticals is one of the most popular companies on Eulerpool.com.

Eiger BioPharmaceuticals SWOT Analysis

Strengths

Eiger BioPharmaceuticals Inc has several key strengths that contribute to its success:

  • Strong product pipeline with innovative and promising drugs
  • Robust research and development capabilities
  • Experienced and knowledgeable management team
  • Strong partnerships with reputable pharmaceutical companies
  • Solid financial position

Weaknesses

Despite its strengths, Eiger BioPharmaceuticals Inc also faces certain weaknesses:

  • Relatively small market presence compared to established competitors
  • Limited marketing and distribution capabilities
  • Dependence on a few key drugs in its portfolio
  • Vulnerability to regulatory changes and approvals

Opportunities

Eiger BioPharmaceuticals Inc can leverage the following opportunities to further grow:

  • Expanding market for its targeted therapies
  • Increasing demand for innovative and effective drugs
  • Collaborations and partnerships for research and development
  • Access to funding for further expansion

Threats

Eiger BioPharmaceuticals Inc faces the following threats that may impact its business:

  • Intense competition from larger and well-established pharmaceutical companies
  • Stringent regulatory requirements and approval processes
  • Economic uncertainties and market fluctuations
  • Emerging technologies and alternative treatment options

Eiger BioPharmaceuticals Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eiger BioPharmaceuticals Revenue by Segment

Segmente2023
Product revenue, net15.52 M USD
Other revenue250,000 USD

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eiger BioPharmaceuticals Revenue by Segment

Segmente2023
Autorisation Temporaire D Utlisation Member2.4 M USD

Eiger BioPharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Eiger BioPharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Eiger BioPharmaceuticals shares outstanding

The number of shares was Eiger BioPharmaceuticals in 2023 — This indicates how many shares 1.476 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Eiger BioPharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Eiger BioPharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Eiger BioPharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Eiger BioPharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eiger BioPharmaceuticals stock splits

In Eiger BioPharmaceuticals's history, there have been no stock splits.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Eiger BioPharmaceuticals.

Eiger BioPharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-9.9 -12.3  (-24.19 %)2023 Q3
6/30/2023-12.55 -14.1  (-12.39 %)2023 Q2
3/31/2023-14.47 -15.6  (-7.78 %)2023 Q1
12/31/2022-16.63 -17.1  (-2.8 %)2022 Q4
9/30/2022-0.53 -0.62  (-16.59 %)2022 Q3
6/30/2022-0.62 -0.51  (17.56 %)2022 Q2
3/31/2022-0.66 -0.64  (2.45 %)2022 Q1
12/31/2021-0.65 -0.64  (1.93 %)2021 Q4
9/30/2021-0.57 -0.65  (-13.6 %)2021 Q3
6/30/2021-0.56 -0.57  (-2.13 %)2021 Q2
1
2
3
4

Eiger BioPharmaceuticals shareholders

%
Name
Stocks
Change
Date
16.05007 % Columbia Threadneedle Investments (US)237,541-36,23112/31/2023
10.09264 % Arkin (Moshe)149,371-3311/14/2023
9.89061 % Propel Bio Management, LLC146,381-32,79312/31/2023
4.72973 % 683 Capital Management LLC70,000-18,33312/31/2023
4.10081 % The Vanguard Group, Inc.60,692-4,78512/31/2023
1.28088 % BlackRock Institutional Trust Company, N.A.18,957-9,38612/31/2023
0.85520 % Geode Capital Management, L.L.C.12,657012/31/2023
0.85432 % Columbia Threadneedle Investments (UK)12,644012/31/2023
0.77703 % Telemetry Investments, L.L.C.11,5005,55012/31/2022
0.77527 % Renaissance Technologies LLC11,47411,47412/31/2023
1
2
3
4
5
...
10

Most common questions regarding Eiger BioPharmaceuticals

What values and corporate philosophy does Eiger BioPharmaceuticals represent?

Eiger BioPharmaceuticals Inc represents innovation, dedication, and excellence in the biopharmaceutical industry. Founded on the principle of advancing novel therapies for rare and ultra-rare diseases, Eiger BioPharmaceuticals Inc is committed to improving patients' lives by developing cutting-edge treatments. The company's corporate philosophy revolves around scientific rigor, collaboration, and patient-centered focus. Eiger BioPharmaceuticals Inc's unwavering commitment to scientific integrity and breakthrough innovations drives their mission to bring transformative medicines to patients globally. With a focus on meeting unmet medical needs, Eiger BioPharmaceuticals Inc continues to push boundaries in drug development, making it a leader in the biopharmaceutical sector.

In which countries and regions is Eiger BioPharmaceuticals primarily present?

Eiger BioPharmaceuticals Inc primarily operates in the United States. The company is based in Palo Alto, California and focuses on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases. With a strong presence in the U.S. healthcare sector, Eiger BioPharmaceuticals Inc operates within the dynamic and innovative biotechnology industry. Their dedication to finding solutions for unmet medical needs has positioned them as a prominent player in the U.S. market.

What significant milestones has the company Eiger BioPharmaceuticals achieved?

Eiger BioPharmaceuticals Inc has achieved several significant milestones. The company successfully completed a Phase 2 ULTRA clinical study for Lonafarnib in Hepatitis Delta Virus (HDV) infection, demonstrating positive results. Furthermore, Eiger initiated Phase 3 D-LIVR study evaluating Lonafarnib in HDV patients, displaying its commitment to advanced treatments. Additionally, the company received Breakthrough Therapy Designation from the FDA for its drug Avexitide in Post-Bariatric Hypoglycemia, acknowledging its potential to fill an unmet medical need. Eiger BioPharmaceuticals Inc continues to make strides in developing innovative therapies and improving patient outcomes in various disease areas.

What is the history and background of the company Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals Inc is a pharmaceutical company specializing in the development of targeted therapies for rare diseases. Founded in 2008, the company is headquartered in Palo Alto, California. Eiger BioPharmaceuticals focuses on developing innovative treatments for diseases such as Hepatitis Delta Virus (HDV) infection, which currently has no approved therapies. With a dedicated team of scientists and researchers, Eiger BioPharmaceuticals has made significant progress in advancing potential breakthrough treatments and has successfully conducted various clinical trials. The company's commitment to addressing unmet medical needs and their expertise in rare diseases make them a key player in the biopharmaceutical industry.

Who are the main competitors of Eiger BioPharmaceuticals in the market?

The main competitors of Eiger BioPharmaceuticals Inc in the market are companies like Gilead Sciences, Vertex Pharmaceuticals, and Intercept Pharmaceuticals.

In which industries is Eiger BioPharmaceuticals primarily active?

Eiger BioPharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals Inc's business model focuses on developing and commercializing innovative therapies for rare and ultra-rare diseases. The company aims to address unmet medical needs and improve the lives of patients with limited treatment options. Eiger BioPharmaceuticals primarily focuses on developing targeted therapies that modulate the underlying disease pathways, aiming to provide safe and effective treatment options. With a strong emphasis on research and development, the company collaborates with leading academic institutions and partners to advance its pipeline of potential therapies. By leveraging its expertise in drug discovery and development, Eiger BioPharmaceuticals aims to bring novel treatments to market and make a positive impact in the healthcare industry.

What is the P/E ratio of Eiger BioPharmaceuticals 2024?

The Eiger BioPharmaceuticals P/E ratio is -0.53.

What is the P/S ratio of Eiger BioPharmaceuticals 2024?

The Eiger BioPharmaceuticals P/S ratio is 0.49.

What is the Quality Investing of Eiger BioPharmaceuticals?

The Quality Investing for Eiger BioPharmaceuticals is 5/10.

What is the revenue of Eiger BioPharmaceuticals 2024?

The expected Eiger BioPharmaceuticals revenue is 25.72 M USD.

How high is the profit of Eiger BioPharmaceuticals 2024?

The expected Eiger BioPharmaceuticals profit is -23.55 M USD.

What is the business model of Eiger BioPharmaceuticals

Eiger BioPharmaceuticals Inc is a biotechnology company focused on the development and commercialization of innovative therapies. The company specializes in developing therapies for rare and life-threatening diseases that have no adequate treatment. Its business model is based on the discovery, development, and marketing of novel therapeutic products. It currently focuses on developing therapies in four different areas specializing in rare and life-threatening diseases: Hepatitis Delta (HDV), Pulmonary Arterial Hypertension (PAH), Lysosomal Storage Diseases (LSD), and COVID-19. The company has its own clinical development organization and proprietary technology called EigerOneTM. Eiger BioPharmaceuticals invests in research and development, holds patents and intellectual property, and has an international presence and partnerships to accelerate research efforts. Overall, its goal is to provide innovative solutions for patients with rare and life-threatening diseases.

What is the Eiger BioPharmaceuticals dividend?

Eiger BioPharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Eiger BioPharmaceuticals pay dividends?

The dividend cannot currently be calculated for Eiger BioPharmaceuticals or the company does not pay out a dividend.

What is the Eiger BioPharmaceuticals ISIN?

The ISIN of Eiger BioPharmaceuticals is US28249U1051.

What is the Eiger BioPharmaceuticals WKN?

The WKN of Eiger BioPharmaceuticals is A2AF9X.

What is the Eiger BioPharmaceuticals ticker?

The ticker of Eiger BioPharmaceuticals is EIGR.

How much dividend does Eiger BioPharmaceuticals pay?

Over the past 12 months, Eiger BioPharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eiger BioPharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Eiger BioPharmaceuticals?

The current dividend yield of Eiger BioPharmaceuticals is .

When does Eiger BioPharmaceuticals pay dividends?

Eiger BioPharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Eiger BioPharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eiger BioPharmaceuticals located?

Eiger BioPharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eiger BioPharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eiger BioPharmaceuticals from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Eiger BioPharmaceuticals pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Eiger BioPharmaceuticals in the year 2023?

In the year 2023, Eiger BioPharmaceuticals distributed 0 USD as dividends.

In which currency does Eiger BioPharmaceuticals pay out the dividend?

The dividends of Eiger BioPharmaceuticals are distributed in USD.

All fundamentals about Eiger BioPharmaceuticals

Our stock analysis for Eiger BioPharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eiger BioPharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.